PhD, Director of Antibody Validation & Characterization, Abcam
Will Howat joined Abcam in August 2018 and is responsible for leading the global Imaging and Immunohistochemistry team. Prior to joining Abcam, he worked at AstraZeneca as the Team Leader of the Molecular Pathology Group, where his team developed biomarker assays for preclinical, Phase 1 and Phase 2 clinical trials. Before that he was at the Cancer Research UK Cambridge Institute where he set up and ran the Histopathology/ISH core facility for 9 years. He has also worked at the Wellcome Sanger Institute on the Atlas of Protein Expression and was responsible for the R&D for the Immunohistochemistry group. Will has a BSc (Hons) in Immunology & Pharmacology from the University of Strathclyde and a PhD in Pathology from the University of Southampton. He has first-author publications in the Lancet, American Journal of Pathology and Journal of Pathology as well as co-authored publications in Nature, Science, Nature Genetics, and Journal of Experimental Medicine.
The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high-quality specific results compared to spurious, non-specific antibody staining on tissue will be easier and allow the researcher to focus on downstream applications, such as single and multiplex IHC.
The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high-quality specific results compared to spurious, non-specific antibody staining on tissue will be easier and allow the researcher to focus on downstream applications, such as single and multiplex IHC.
